Gleevec Decreases Cancer Recurrence for Patients with a Type of Gastrointestinal Cancer


Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

This study was funded by the National Cancer Institute

Journalists may contact the Department of Public Affairs for more information.
Telephone: 212-639-3573